A potent vasodilator and inhibitor of platelet aggregation
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Prostaglandin I2 (sodium salt)

Item No. 18220

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
6,9α-epoxy-11α,15S-dihydroxy-prosta-5Z,13E-dien-1-oic acid, monosodium salt
CAS Number
61849-14-7
Synonyms
  • Epoprostenol
  • PGI2
  • Prostacyclin
Molecular Formula
C20H31O5 • Na
Formula Weight
374.5
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 5 mg/mlDMSO: 5 mg/mlEthanol: 10 mg/ml*PBS (pH >10.2): 10 mg/mlWater: 10 mg/ml
SMILES
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@H]2[C@@H]1C/C(O2)=C/CCCC([O-])=O.[Na+]
InChi Code
InChI=1S/C20H32O5.Na/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22;/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24);/q;+1/p-1/b11-10+,15-8-;/t14-,16+,17+,18+,19-;/m0./s1
InChi Key
LMHIPJMTZHDKEW-XQYLJSSYSA-M
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $87

    Add

    5 mg

    $392

    Add

    10 mg

    $696

    Add

    25 mg

    $1,522

    Add
    Lipid Resource Center
    Discover Products & Resources for Lipid Research
    • High-purity lipid standards
    • Lipid roles in biology
    • Lipids in health & disease
    • Lipids for pharmaceutical development
    • Protocols, advice, & resources
    EXPLORE NOW
    Product Description

    Prostaglandin I2 (PGI2) is an unstable cyclooxygenase metabolite detected first in vascular endothelial cells.1,2,3 It elevates platelet cAMP and is a potent vasodilator and inhibitor of human platelet aggregation with an IC50 of 5 nM.4 PGI2 is stable in basic buffers (pH=8), but it is rapidly hydrolyzed to 6-keto PGF1α in neutral or acidic solutions. The half-life is short both in vivo and in vitro, ranging from 30 seconds to a few minutes. PGI2 is administered by continuous infusion in humans for the treatment of idiopathic pulmonary hypertension.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Moncada, S., Gryglewski, R., Bunting, S., et al. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263(5579), 663-665 (1976).

    2. Johnson, R.A., Morton, D.R., Kinner, J.H., et al. The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 12(6), 915-928 (1976).

    3. Stehle, R.G. Physical chemistry, stability, and handling of prostaglandins E2, F2α, D2 and I2: A critical summary. Methods Enzymol. 86, 436-459 (1982).

    4. Aristoff, P.A., Johnson, P.D., and Harrison, A.W. Synthesis of 9-substituted carbacyclin analogues. The Journal of Organic Chemistry 48(26), 5341-5348 (1983).

    5. McLaughlin, V.V., Genthner, D.E., Panella, M.M., et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N. Engl. J. Med. 338(5), 273-277 (1998).